Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000072.xml
Download PDF
Semin Reprod Med
DOI: 10.1055/s-0045-1809186
DOI: 10.1055/s-0045-1809186
Review Article
Progestogens in Menopausal Hormone Therapy: A Double-Edged Sword
Abstract
Progestogens (norethisterone acetate, medroxyprogesterone acetate, dydrogesterone, micronized progesterone, levonorgestrel, drospirenone, and trimegestone) added to estrogen for endometrial protection are reviewed. They can be given orally or vaginally, norethisterone acetate can also be given transdermally, and levonorgestrel can be given through the intrauterine route. Sequential use of progestogens protects the endometrium if exposure lasts for at least 12 days/month; longer intervals are not safe. Continuous use of progestogens, whether oral, transdermal, or intrauterine, provides the most effective protection. Progestogen addition is accompanied with significant elevations in breast cancer risk, the largest drawback of progestogen use, and dydrogesterone, micronized progesterone, and a levonorgestrel intrauterine device may be safest in this regard. Progestogens also double deep vein thrombosis risk and diminish the positive effect of estrogen on colorectal cancer and vascular health. Recent data imply a neutral effect of progestogens in combination with estrogen on Alzheimer's disease risk, but the risk of vascular dementia is decreased. In conclusion, progestogens are a double-edged sword, effectively protecting the endometrium but causing several side effects and reducing many estrogen-induced benefits. With modern endometrial diagnostic tools, the safety of low-dose unopposed estrogen regimens should be assessed in a prospective controlled trial in women with an intact uterus.
Publication History
Article published online:
16 May 2025
© 2025. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Gold EB, Bromberger J, Crawford S. et al. Factors associated with age at natural menopause in a multiethnic sample of midlife women. Am J Epidemiol 2001; 153 (09) 865-874
- 2 Nichols HB, Trentham-Dietz A, Hampton JM. et al. From menarche to menopause: trends among US women born from 1912 to 1969. Am J Epidemiol 2006; 164 (10) 1003-1011
- 3 Faubion SS, Crandall CJ, Davis L. et al; “The 2022 Hormone Therapy Position Statement of the North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of the North American Menopause Society. Menopause 2022; 29 (07) 767-794
- 4 Lambrinoudaki I, Armeni E, Goulis D. et al. Menopause, wellbeing and health: a care pathway from the European Menopause and Andropause Society. Maturitas 2022; 163: 1-14
- 5 Grimm SL, Hartig SM, Edwards DP. Progesterone receptor signaling mechanisms. J Mol Biol 2016; 428 (19) 3831-3849
- 6 DeMayo FJ, Lydon JP. 90 years of progesterone: new insights into progesterone receptor signaling in the endometrium required for embryo implantation. J Mol Endocrinol 2020; 65 (01) T1-T14
- 7 Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 2005; 8 (1, Suppl 1): 3-63
- 8 Dinh A, Sriprasert I, Williams AR, Archer DF. A review of the endometrial histologic effects of progestins and progesterone receptor modulators in reproductive age women. Contraception 2015; 91 (05) 360-367
- 9 García-Sáenz M, Ibarra-Salce R, Pozos-Varela FJ. et al. Understanding progestins: from basics to clinical applicability. J Clin Med 2023; 12 (10) 3388
- 10 Palmisano BT, Zhu L, Stafford JM. Role of estrogens in the regulation of liver lipid metabolism. Adv Exp Med Biol 2017; 227-256
- 11 Chiarella SE, Buchheit KM, Foer D. Progestogen hypersensitivity. J Allergy Clin Immunol Pract 2023; 11 (12) 3606-3613.e2
- 12 Stute P, Walker LJ, Eicher A. et al. Progestogens for endometrial protection in combined menopausal hormone therapy: a systematic review. Best Pract Res Clin Endocrinol Metab 2024; 38 (01) 101815
- 13 Van Voorhis BJ, Santoro N, Harlow S, Crawford SL, Randolph J. The relationship of bleeding patterns to daily reproductive hormones in women approaching menopause. Obstet Gynecol 2008; 112 (01) 101-108
- 14 Joensuu JM, Ylikorkala O, Venetkoski M, Gissler M, Savolainen-Peltonen H, Mikkola TS. Frequent use of premenopausal progestin in prior pre-eclamptic women. J Clin Endocrinol Metab 2024; dgae677
- 15 Jordao H, Herink K, Ka E, McVicker L, Kearns C, McMenamin ÚC. Pre-eclampsia during pregnancy and risk of endometrial cancer: a systematic review and meta-analysis. BMC Womens Health 2023; 23 (01) 259
- 16 Wang F, Zhang W, Cheng W, Huo N, Zhang S. Preeclampsia and cancer risk in women in later life: a systematic review and meta-analysis of cohort studies. Menopause 2021; 28 (09) 1070-1078
- 17 Judd HL, Mebane-Sims I, Legault C. et al; The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996; 275 (05) 370-375
- 18 Fournier A, Dossus L, Mesrine S. et al. Risks of endometrial cancer associated with different hormone replacement therapies in the E3N cohort, 1992-2008. Am J Epidemiol 2014; 180 (05) 508-517
- 19 Jaakkola S, Lyytinen H, Pukkala E, Ylikorkala O. Endometrial cancer in postmenopausal women using estradiol-progestin therapy. Obstet Gynecol 2009; 114 (06) 1197-1204
- 20 Beral V, Bull D, Reeves G. Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005; 365 (9470) 1543-1551
- 21 Brinton LA, Felix AS. Menopausal hormone therapy and risk of endometrial cancer. J Steroid Biochem Mol Biol 2014; 142: 83-89
- 22 Hamoda H, Moger S. Board of Trustees and Medical Advisory Council of the British Menopause Society. Developing the women's health strategy: the British Menopause Society's recommendations to the department of health and social care's call for evidence. Post Reprod Health 2022; 28 (01) 13-18
- 23 Raudaskoski TH, Lahti EI, Kauppila AJ, Apaja-Sarkkinen MA, Laatikainen TJ. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses. Am J Obstet Gynecol 1995; 172 (1, Pt 1): 114-119
- 24 Suhonen SP, Allonen HO, Lähteenmäki P. Sustained-release estradiol implants and a levonorgestrel-releasing intrauterine device in hormone replacement therapy. Am J Obstet Gynecol 1995; 172 (2, Pt 1): 562-567
- 25 Clark K, Westberg SM. Benefits of levonorgestrel intrauterine device use vs. oral or transdermal progesterone for postmenopausal women using estrogen containing hormone therapy. Innov Pharm 2019;10(03):
- 26 Dominick S, Hickey M, Chin J, Su HI. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database Syst Rev 2015; 2015 (12) CD007245
- 27 Mittermeier T, Farrant C, Wise MR. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia. Cochrane Database Syst Rev 2020; 9 (09) CD012658
- 28 de Medeiros SF, Yamamoto MMW, Barbosa JS. Abnormal bleeding during menopause hormone therapy: insights for clinical management. Clin Med Insights Womens Health 2013; 6: 13-24
- 29 Huvinen E, Holopainen E, Heikinheimo O. Norethisterone and its acetate - what's so special about them?. BMJ Sex Reprod Health 2021; 47 (02) 102-109
- 30 Navarrete MAH, Maier CM, Falzoni R. et al. Assessment of the proliferative, apoptotic and cellular renovation indices of the human mammary epithelium during the follicular and luteal phases of the menstrual cycle. Breast Cancer Res 2005; 7 (03) R306-R313
- 31 Sung H, Ferlay J, Siegel RL. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249
- 32 Speroff L. Postmenopausal hormone therapy and the risk of breast cancer: a contrary thought. Menopause 2008; 15 (02) 393-400
- 33 Rossouw JE, Anderson GL, Prentice RL. et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288 (03) 321-333
- 34 Prentice RL, Aragaki AK, Chlebowski RT. et al. Randomized trial evaluation of the benefits and risks of menopausal hormone therapy among women 50–59 years of age. Am J Epidemiol 2021; 190 (03) 365-375
- 35 Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2017; 1 (01) CD004143
- 36 Yang Z, Hu Y, Zhang J, Xu L, Zeng R, Kang D. Estradiol therapy and breast cancer risk in perimenopausal and postmenopausal women: a systematic review and meta-analysis. Gynecol Endocrinol 2017; 33 (02) 87-92
- 37 Baik SH, Baye F, McDonald CJ. Use of menopausal hormone therapy beyond age 65 years and its effects on women's health outcomes by types, routes, and doses. Menopause 2024; 31 (05) 363-371
- 38 Luoto R, Auvinen A, Pukkala E, Hakama M. Hysterectomy and subsequent risk of cancer. Int J Epidemiol 1997; 26 (03) 476-483
- 39 Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 2019; 394 (10204): 1159-1168
- 40 Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases. BMJ 2020; 371: m3873
- 41 Siitonen H, Joensuu J, Savolainen-Peltonen H, Gissler M, Ylikorkala O, Mikkola TS. Update of the impact of menopausal hormone therapy on breast cancer risk. Eur J Cancer 2025; 220: 115340
- 42 Cartwright M, Toit RL, Africander D. The transcriptional activity of progestins used in contraception and menopausal hormone therapy via progesterone receptor A is dependent on the density of the receptor. Biochem Biophys Res Commun 2023; 639: 70-76
- 43 Louw-du Toit R, Simons M, Africander D. Progestins and breast cancer hallmarks: the role of the ERK1/2 and JNK pathways in estrogen receptor positive breast cancer cells. J Steroid Biochem Mol Biol 2024; 237: 106440
- 44 Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol 2009; 113 (01) 65-73
- 45 Lyytinen HK, Dyba T, Ylikorkala O, Pukkala EI. A case-control study on hormone therapy as a risk factor for breast cancer in Finland: intrauterine system carries a risk as well. Int J Cancer 2010; 126 (02) 483-489
- 46 Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008; 107 (01) 103-111
- 47 Memi E, Pavli P, Maria P, Vrachnis N, Mastorakos G. Diagnostic and therapeutic use of oral micronized progesterone in endocrinology. Rev Endocr Metab Disord 2024; 25 (04) 751-772
- 48 Raudaskoski T, Tapanainen J, Tomás E. et al. Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. BJOG 2002; 109 (02) 136-144
- 49 Zürcher A, Knabben L, Janka H, Stute P. Influence of the levonorgestrel-releasing intrauterine system on the risk of breast cancer: a systematic review. Arch Gynecol Obstet 2023; 307 (06) 1747-1761
- 50 Yi H, Zhang N, Huang J. et al. Association of levonorgestrel-releasing intrauterine device with gynecologic and breast cancers: a national cohort study in Sweden. Am J Obstet Gynecol 2024; 231 (04) 450.e1-450.e12
- 51 Mørch LS, Lidegaard Ø, Keiding N, Løkkegaard E, Kjær SK. The influence of hormone therapies on colon and rectal cancer. Eur J Epidemiol 2016; 31 (05) 481-489
- 52 Zhang GQ, Chen JL, Luo Y. et al. Menopausal hormone therapy and women's health: an umbrella review. PLoS Med 2021; 18 (08) e1003731
- 53 Hodis HN, Mack WJ. Menopausal hormone replacement therapy and reduction of all-cause mortality and cardiovascular disease: it is about time and timing. Cancer J 2022; 28 (03) 208-223
- 54 Hildebrand JS, Jacobs EJ, Campbell PT. et al. Colorectal cancer incidence and postmenopausal hormone use by type, recency, and duration in cancer prevention study II. Cancer Epidemiol Biomarkers Prev 2009; 18 (11) 2835-2841
- 55 Beral V, Reeves G, Bull D, Green J. Million Women Study C. Bull Green J Reeves G Ovarian Cancer Horm Replace Ther Million Women Study Lancet. 2007; 369 (9574) 1703-1710
- 56 Koskela-Niska V, Pukkala E, Lyytinen H, Ylikorkala O, Dyba T. Effect of various forms of postmenopausal hormone therapy on the risk of ovarian cancer – a population-based case control study from Finland. Int J Cancer 2013; 133 (07) 1680-1688
- 57 Lee AW, Ness RB, Roman LD. et al; Ovarian Cancer Association Consortium. Association between menopausal estrogen-only therapy and ovarian carcinoma risk. Obstet Gynecol 2016; 127 (05) 828-836
- 58 Koskela-Niska V, Lyytinen H, Riska A, Pukkala E, Ylikorkala O. Ovarian cancer risk in postmenopausal women using estradiol-progestin therapy - a nationwide study. Climacteric 2013; 16 (01) 48-53
- 59 Koskela-Niska V, Riska A, Lyytinen H, Pukkala E, Ylikorkala O. Primary fallopian tube carcinoma risk in users of postmenopausal hormone therapy in Finland. Gynecol Oncol 2012; 126 (02) 241-244
- 60 Mikkola TS, Gissler M, Merikukka M, Tuomikoski P, Ylikorkala O. Sex differences in age-related cardiovascular mortality. PLoS One 2013; 8 (05) e63347
- 61 Tsao CW, Aday AW, Almarzooq ZI. et al. Heart disease and stroke statistics—2022 update: a report from the American Heart Association. Circulation 2022; 145 (08) e153-e639
- 62 Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 2002; 53 (03) 605-619
- 63 Boardman HM, Hartley L, Eisinga A. et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 2015; 2015 (03) CD002229
- 64 Hodis HN, Mack WJ, Henderson VW. et al; ELITE Research Group. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med 2016; 374 (13) 1221-1231
- 65 Gersh F, O'Keefe JH, Elagizi A, Lavie CJ, Laukkanen JA. Estrogen and cardiovascular disease. Prog Cardiovasc Dis 2024; 84: 60-67
- 66 Nudy M, Buerger J, Dreibelbis S, Jiang X, Hodis HN, Schnatz PF. Menopausal hormone therapy and coronary heart disease: the roller-coaster history. Climacteric 2024; 27 (01) 81-88
- 67 Hulley S, Grady D, Bush T. et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280 (07) 605-613
- 68 Rossouw JE, Prentice RL, Manson JE. et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297 (13) 1465-1477
- 69 Stute P, Marsden J, Salih N, Cagnacci A. Reappraising 21 years of the WHI study: putting the findings in context for clinical practice. Maturitas 2023; 174: 8-13
- 70 Gu Y, Han F, Xue M, Wang M, Huang Y. The benefits and risks of menopause hormone therapy for the cardiovascular system in postmenopausal women: a systematic review and meta-analysis. BMC Womens Health 2024; 24 (01) 60
- 71 Johansson T, Karlsson T, Bliuc D. et al. Contemporary menopausal hormone therapy and risk of cardiovascular disease: Swedish nationwide register based emulated target trial. BMJ 2024; 387: e078784
- 72 Savolainen-Peltonen H, Tuomikoski P, Korhonen P. et al. Cardiac death risk in relation to the age at initiation or the progestin component of hormone therapies. J Clin Endocrinol Metab 2016; 101 (07) 2794-2801
- 73 Vehkavaara S, Silveira A, Hakala-Ala-Pietilä T. et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001; 85 (04) 619-625
- 74 Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ 2019; 364: k4810
- 75 Strandberg TE, Ylikorkala O, Tikkanen MJ. Differing effects of oral and transdermal hormone replacement therapy on cardiovascular risk factors in healthy postmenopausal women. Am J Cardiol 2003; 92 (02) 212-214
- 76 Vehkavaara S, Hakala-Ala-Pietilä T, Virkamäki A. et al. Differential effects of oral and transdermal estrogen replacement therapy on endothelial function in postmenopausal women. Circulation 2000; 102 (22) 2687-2693
- 77 Mohammed K, Abu Dabrh AM, Benkhadra K. et al. Oral vs transdermal estrogen therapy and vascular events: a systematic review and meta-analysis. J Clin Endocrinol Metab 2015; 100 (11) 4012-4020
- 78 Pan Z, Wen S, Qiao X, Yang M, Shen X, Xu L. Different regimens of menopausal hormone therapy for improving sleep quality: a systematic review and meta-analysis. Menopause 2022; 29 (05) 627-635
- 79 Graff-Radford J, Yong KXX, Apostolova LG. et al. New insights into atypical Alzheimer's disease in the era of biomarkers. Lancet Neurol 2021; 20 (03) 222-234
- 80 Morinaga A, Hirohata M, Ono K, Yamada M. Estrogen has anti-amyloidogenic effects on Alzheimer's β-amyloid fibrils in vitro. Biochem Biophys Res Commun 2007; 359 (03) 697-702
- 81 Maki PM. Critical window hypothesis of hormone therapy and cognition: a scientific update on clinical studies. Menopause 2013; 20 (06) 695-709
- 82 Gleason CE, Dowling NM, Kara F. et al. Long-term cognitive effects of menopausal hormone therapy: findings from the KEEPS Continuation Study. PLoS Med 2024; 21 (11) e1004435
- 83 Andy C, Nerattini M, Jett S. et al. Systematic review and meta-analysis of the effects of menopause hormone therapy on cognition. Front Endocrinol (Lausanne) 2024; 15: 1350318
- 84 Savolainen-Peltonen H, Rahkola-Soisalo P, Hoti F. et al. Use of postmenopausal hormone therapy and risk of Alzheimer's disease in Finland: nationwide case-control study. BMJ 2019; 364: l665
- 85 Mikkola TS, Savolainen-Peltonen H, Tuomikoski P. et al. Lower death risk for vascular dementia than for Alzheimer's disease with postmenopausal hormone therapy users. J Clin Endocrinol Metab 2017; 102 (03) 870-877
- 86 Cherry N, McNamee R, Heagerty A, Kitchener H, Hannaford P. Long-term safety of unopposed estrogen used by women surviving myocardial infarction: 14-year follow-up of the ESPRIT randomised controlled trial. BJOG 2014; 121 (06) 700-705 , discussion 705